The investment bank previously had a Neutral rating for the company, and it lowered the price target on Genomic Health's stock to $25 from $28.
Genomic Health will test samples from Janssen prostate cancer drug studies to examine whether its test can predict patient outcomes.
Under the terms of the five-year deal, pharmaceutical company Ferrer will sell SelectMDx test directly to urologists in Spain.
A tumor sequencing study suggests the retention or deletion of interstitial genes within the TMPRSS2-ERG gene fusion may coincide with prostate cancer progression.
The company discussed expectations for how its products will fare against rivals into next year based on recent data and coverage decisions, and on expected reimbursement changes.
Test volume was up 5 percent, but the company's total revenue of $83.8 million was negatively affected by hurricanes in the US, company executives said.
Excluding revenues from the sale of MDxHealth's colorectal cancer patents to Exact Sciences, total revenues increased approximately 3 percent for the period.
Unilabs will perform the test in Switzerland and offer it throughout its network of clinical labs in Europe, including France, the UK, Sweden, and other countries.
Two studies led by Cleveland Clinic researchers found that a variant in a gene involved in androgen synthesis can help predict response to different prostate cancer therapies.
The company hopes to build enrollment of men with advanced prostate cancer within its larger Strata Trial — which provides free targeted sequencing and tracks its impact on clinical trial enrollment.
A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.
The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.
Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.
In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.